Loading…
Takeda Pharmaceutical Company Limited is projected to rise to $21.82 by 2027, a +32% move from its current price of $16.56. TAK is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $16.38 | $16.56 | $16.75 | +0.02% |
| Jul 15 | $16.30 | $16.57 | $16.83 | +0.04% |
| Jul 16 | $16.25 | $16.57 | $16.90 | +0.05% |
| Jul 17 | $16.20 | $16.57 | $16.95 | +0.07% |
| Jul 18 | $16.16 | $16.57 | $17.00 | +0.09% |
| Jul 19 | $16.12 | $16.58 | $17.04 | +0.11% |
| Jul 20 | $16.09 | $16.58 | $17.09 | +0.12% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $16.09 | $16.58 | $17.09 | +0.12% |
| Week 2 | $15.91 | $16.60 | $17.32 | +0.25% |
| Week 3 | $15.78 | $16.62 | $17.51 | +0.37% |
| Week 4 | $15.67 | $16.64 | $17.67 | +0.49% |
| Week 5 | $15.58 | $16.66 | $17.82 | +0.62% |
| Week 6 | $15.50 | $16.68 | $17.96 | +0.74% |
| Week 7 | $15.43 | $16.70 | $18.08 | +0.86% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Takeda Pharmaceutical Company Limited is a healthcare company that engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.
The company provides its products under Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio.
The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.
Takeda is currently priced at $16.77 with a market cap of $52.99B and a market-rank of 291. The overall price outlook shows upside over the forecast horizon, with a neutral stance for 2026 and stronger upside potential in later years.
The forecast path starts with 2026 min $15.03, avg $16.77, max $22.07 and sentiment Neutral, followed by a bullish trajectory in 2027–2050 as the average price climbs toward the mid-to-high range of the forecast and max values rise substantially. By 2050 the forecasted average reaches $128.31 with a max of $209.82 and a very high upside potential (665.1% max ROI), signaling a pronounced long-term bullish outlook.
A major floor 13.9% below — a decisive break under it would weaken the trend.
The nearest floor, 9.2% below — buyers have tended to step in here.
Price is pressing into resistance (2.4% away) — a breakout level to watch.
A major ceiling 13.3% above — clearing it would confirm fresh momentum.
Key TAK support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TAK market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $16.75 | Sell | $16.61 | Sell |
| MA 10 | $16.44 | Buy | $16.45 | Buy |
| MA 20 | $16.07 | Buy | $16.24 | Buy |
| MA 50 | $16.14 | Buy | $16.31 | Buy |
| MA 100 | $17.08 | Sell | $16.46 | Buy |
| MA 200 | $16.08 | Buy | $16.19 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.80 | Neutral |
| Stoch RSI (14) | 64.65 | Neutral |
| CCI (20) | 79.40 | Neutral |
| Williams %R (14) | -26.85 | Info |
| MACD (12,26,9) | 0.12 | Buy |
| ROC (12) | 4.55 | Buy |
| Bollinger %B (20,2) | 0.76 | Neutral |
| Stochastic %K (14) | 73.15 | Neutral |
| TRIX (15) | 0.06 | Buy |
| Awesome (5,34) | 0.82 | Buy |
| Ultimate (7,14,28) | 66.11 | Neutral |
| Momentum (10) | 0.91 | Buy |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 16.83 | Sell |
| ADX (14) | 19.39 | Neutral |
| ATR (14) | 0.17 | Info |
The 30-day technical picture is bullish, with RSI14 at 70 indicating strong momentum. The stock trades above the key moving averages, with SMA50 at $16.11 and SMA200 at $16.04, suggesting near-term price support around the mid-$16s.
In the near term, Takeda sits in a 30-day range from $15.43 to $18.23, with resistance at $16.77 and support at $15.03. This structure points to a constructive setup, though the stock could pause near the near-term resistance as momentum remains elevated.
Annualized volatility stands at 20%, reflecting a degree of swing in price that is typical for this sector.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $15.03 | $16.56 | $21.49 | 0% | Neutral | |
| $17.87 | $21.82 | $27.86 | +32% | Bullish | |
| $19.33 | $24.04 | $31.52 | +45% | Bullish | |
| $20.83 | $26.31 | $35.22 | +59% | Bullish | |
| $22.88 | $29.29 | $39.92 | +77% | Bullish | |
| $22.87 | $29.63 | $41.03 | +79% | Bullish | |
| $24.51 | $32.11 | $45.10 | +94% | Bullish | |
| $26.84 | $35.55 | $50.56 | +115% | Bullish | |
| $29.98 | $40.10 | $57.72 | +142% | Bullish | |
| $35.27 | $47.62 | $69.31 | +188% | Bullish | |
| $41.96 | $59.08 | $90.11 | +257% | Bullish | |
| $83.23 | $125.69 | $205.50 | +659% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $15.03 | $16.56 | $19.31 | +0.00% |
| August 2026 | $14.09 | $16.49 | $19.71 | -0.44% |
| September 2026 | $14.31 | $16.83 | $20.27 | +2.06% |
| October 2026 | $14.17 | $16.73 | $20.29 | -0.59% |
| November 2026 | $14.20 | $16.82 | $20.52 | +0.57% |
| December 2026 | $14.75 | $17.53 | $21.49 | +4.22% |
Click any year to see its month-by-month TAK forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The TAK price prediction for 2026 points to an average of $16.56 (low $15.03, high $21.49) — a potential gain of 0% on today's $16.56. A consolidation phase looks the most probable path here.
In 2027, TAK is projected to trade between $17.87 and $27.86, averaging $21.82 — a potential gain of +32% from today's $16.56. That is up +32% on the projected 2026 average. Momentum favours further upside here.
Takeda Pharmaceutical Company Limited's 2028 outlook centres on $24.04, within a $19.33 to $31.52 range. That is up +10% on the projected 2027 average. That marks a +45% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, TAK could reach as high as $35.22, with a base case around $26.31 and support toward $20.83 — roughly +59% from $16.56. Momentum favours further upside here.
Expect TAK to range from $22.88 to $39.92 through 2030. The $29.29 average target implies a +77% move from current prices. That is up +11% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The TAK price prediction for 2031 points to an average of $29.63 (low $22.87, high $41.03) — a potential gain of +79% on today's $16.56. Momentum favours further upside here.
In 2032, TAK is projected to trade between $24.51 and $45.10, averaging $32.11 — a potential gain of +94% from today's $16.56. That is up +8% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Takeda Pharmaceutical Company Limited's 2033 outlook centres on $35.55, within a $26.84 to $50.56 range. That is up +11% on the projected 2032 average. That marks a +115% change versus current levels. Momentum favours further upside here.
By 2034, TAK could reach as high as $57.72, with a base case around $40.10 and support toward $29.98 — roughly +142% from $16.56. Buyers look set to stay in control over this stretch.
Expect TAK to range from $35.27 to $69.31 through 2035. The $47.62 average target implies a +188% move from current prices. That is up +19% on the projected 2034 average. Momentum favours further upside here.
The TAK price prediction for 2040 points to an average of $59.08 (low $41.96, high $90.11) — a potential gain of +257% on today's $16.56. Buyers look set to stay in control over this stretch.
In 2050, TAK is projected to trade between $83.23 and $205.50, averaging $125.69 — a potential gain of +659% from today's $16.56. That is up +113% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in TAK today (≈ 60.386473 TAK) could be worth
$7,589.8
+$6,589.8 (+659%) by 2050 · US Dollar
Based on the average projected TAK price of $125.69 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TAKwould be worth at today's price.
$1,000 invested in TAK on Jul 10, 2025 (≈ 67.385444 TAK) would be worth
$1,115.9
+$115.9 (+11.6%) today · 1.12× · US Dollar
Based on a TAK entry price of $14.84 vs. today's $16.56.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $16.77 | $987.48 | -1.3% |
| 1 month ago | $15.68 | $1,056.12 | +5.6% |
| 3 months ago | $18.08 | $915.93 | -8.4% |
| 6 months ago | $16.26 | $1,018.45 | +1.8% |
| 1 year ago | $14.84 | $1,115.9 | +11.6% |
| All time (5.0y) ago | $17.26 | $959.44 | -4.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TAK forecast.
Our base-case forecast reaches $33.00 around 2033.
Implied market cap at $33.00: $105.39B
The multi-year forecast shows a clear path of rising averages and expanding upside. In 2026 the min is $15.03, avg $16.77, max $22.07 with a neutral sentiment. From 2027 onward the averages rise: $22.01 in 2027, $24.49 in 2028, $26.84 in 2029, and $29.59 in 2030, with corresponding max values and growing bullish sentiment.
The 2030 forecast implies an average price of $29.59 and a max of $40.35 with a 76.4% ROI.
By 2040 the forecast shows an average of $60.14 (min $42.70, max $91.75) and a 258.6% ROI, with sentiment remaining bullish. By 2050 the average is $128.31 (min $84.95, max $209.82) and the max ROI reaches 665.1%, maintaining a bullish outlook. These figures illustrate a steady, long-term upside, but they are estimates and not guarantees.
The path assumes continued expansion and demand across the company’s global footprint and product portfolio, subject to the usual market and regulatory risks.
Tap a question to reveal the answer.
The 2030 forecast shows min $23.10, avg $29.59, max $40.35 with a 76.4% ROI and bullish sentiment.
The outlook moves from neutral in 2026 to bullish in later years, with growing averages and high upside by 2050 (avg $128.31, max $209.82; ROI 665.1%). These are estimates, not guarantees, and depend on market and company factors.
Yes. The 2050 forecast lists a max of $209.82, which exceeds $100, while the average is $128.31.
RSI14 is 70, with SMA50 at $16.11 and SMA200 at $16.04. The 30-day range is $15.43 to $18.23, with resistance at $16.77 and support at $15.03.
Current price is $16.77 and market cap is $52.99B, with a market-rank of 291.
Takeda Pharmaceutical Company Limited Community Discussion
0Share your Takeda Pharmaceutical Company Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.